Clinical Trials · NCT04734730
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- City of Hope Medical Center
- Enrollment
- 70
- Start date
- May 2021
- Locations
- 1 site, United States
- Primary endpoint
- Prostate specific antigen (PSA) nadir < 0.2